Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Shareholder Meeting (April 2023)
17 slides from Bristol-myers Squibb's shareholder meeting presentation, Apr 10, 2023
Slide 1: Proxy Season Update April 2023
Proxy Season Update April 2023
Slide 2: Our Mission, Vision and Values
2 Our Mission To discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our Vision To be the world’s leading biopharma company that transforms patients’ lives through science. Our Values Integrity | Innovation | Urgency | Passion | Accountability | Inclu
Slide 3: 2022 A Year of Strong Performance
2022 A Year of Strong Performance Continued to strengthen our diversified portfolio with leading positions in Oncology, Hematology, Cardiovascular and Immunology Consistent revenues vs. 2021, with 3% growth when adjusted for foreign exchange, driven by robust business performance across our In-Line
Slide 4: 2022 Total Revenues and Key Business Development Transactions
4 4 $46.2B Total Revenues in 2022 Completed Key Business Development Transactions Including the acquisition of Turning Point Therapeutics 21 Approvals (18 approvals in the U.S., EU & JP; 3 approvals in CN) 50+ Early-stage assets 3 First-in-class assets approved in 2022 Balanced Capital Allocation St
Slide 5: Our Commitment to Sustainability
Our Commitment to Sustainability 5 Embracing environmental stewardship Environment 2024 Science-based emissions reduction targets established 2030 100% renewable electricity 2040 Net neutral GHG 100% EV fleet 100% equitable water use Zero waste to landfill Promoting product quality & safety Cultivat
Slide 6: Inclusion & Diversity and Health Equity Goals
Supplier Diversity Employee Giving Workforce Representation Goals Clinical Trial Diversity Reach underserved communities in urban and rural U.S. geographies; train and develop 250 new investigators Identify and activate under-utilized sites in the most racially and ethnically diverse metro areas in
Slide 7: Inclusion & Diversity impact by the numbers
Bristol Myers Squibb and the Bristol Myers Squibb Foundation:Inclusion & Diversity impact by the numbers U.S. executive representation by race/ethnicity2 6.1%of U.S. executives were Black/African American at year-end 2022, an increase from 3.0%, just exceeding goal of 6% 6.1% of U.S. executives were
Slide 8: Board Accountability and Shareholder Rights
8 Board Accountability and Shareholder Rights Regular shareholder engagement Annual election of Directors Majority voting standard for election of Directors Robust Lead Independent Director role Limit on public company board memberships for BMS Directors (4) Limit on total board memberships for sitt
Slide 9: Board Well-Equipped to Support Company Strategies
Board Well-Equipped to Support Company Strategies 9 Audit: Audit Committee CDCG: Committee on Directors & Corporate Governance CMDC: Compensation & Management Development Committee S&T: Science & Technology Committee (c): Committee Chair * = New Since 2022 Giovanni Caforio, M.D. More than 20 years o
Slide 10: Board Key Skills & Experience
Caforio Samuels Arduini Bhatt Haller Hidalgo Medina Price Rice Storch Vousden Yale KEY SKILLS & EXPERIENCE Healthcare Experience in relevant areas within the healthcare industry, including science, manufacturing, regulatory compliance, payer dynamics, and working with health care providers ü ü ü ü ü
Slide 11: Executive Compensation Supporting our Strategy
Executive Compensation Supporting our Strategy 11 Continued Commitment to our Compensation Philosophy and Structure Pay for Performance A substantial proportion of our executives’ pay is variable, at-risk based on our financial and operational results and delivered in the form of equity, supporting
Slide 12: 2022 Compensation Plan: Supports Revenue Renewal & Execution of Core Strategy
2022 Compensation Plan: Supports Revenue Renewal & Execution of Core Strategy* 12 Base Salary Annual Incentive (Paid in cash) Allows us to attract and retain talent in a highly competitive labor market Based on specialized qualifications, experience and role impact, and pay levels of comparable posi
Slide 13: We Value Your Support at Our 2023 Annual Meeting
We Value Your Support at Our 2023 Annual Meeting 13 FOR Election of Directors FOR Advisory Vote to Approve the Compensation of our Named Executive Officers FOR ONE YEAR Advisory Vote on the Frequency of the Advisory Vote on the Compensation of our Named Executive Officers FOR Ratification of the App
Slide 14: Shareholder Proposal on Workplace Non-Discrimination Audit
We Value Your Support at Our 2023 Annual Meeting (continued) 14 Shareholder Proposal on Workplace Non-Discrimination Audit After careful consideration, the Board believes the proposal is not in the best interests of the Company and its shareholders. Our dedication to building and prioritizing a dive
Slide 15: Shareholder Proposal on Special Shareholder Meeting Improvement
We Value Your Support at Our 2023 Annual Meeting (continued) 15 After careful consideration, the Board believes the proposal is not in the best interests of the Company and its shareholders. The Company is committed to high standards of corporate governance, including taking steps to achieve greater
Slide 16: Forward-Looking Statements & Non-GAAP Financial Information
Forward-Looking Statements & Non-GAAP Financial Information This presentation contains statements about the Company’s future financial results, plans, business development strategy, anticipated clinical trials results and regulatory approvals that constitute forward-looking statements for purposes o
Slide 17: 2021 Stock Award and Incentive Plan Proposal
We Value Your Support at Our 2021 Annual Meeting (continued) 12 Management Proposal on the Approval ofCompany’s 2021 Stock Award and Incentive Plan The 2021 Plan is an “omnibus” plan, authorizing a variety of equity award types as well as cash incentive awards. The 2021 Plan is similar in scope to o
Bristol Myers Squibb — Shareholder Meeting (April 2023) on 6ix